Please use this identifier to cite or link to this item: http://hdl.handle.net/20.500.12323/3775
Full metadata record
DC FieldValueLanguage
dc.contributor.authorKhalilova, Irada S.-
dc.contributor.authorDickerhof, Nina-
dc.contributor.authorMocatta, Tessa J.-
dc.contributor.authorBhagra, Catriona J.-
dc.contributor.authorMcClean, Dougal R.-
dc.contributor.authorObinger, Christian-
dc.contributor.authorKettle, Anthony J.-
dc.date.accessioned2018-05-07T07:05:11Z-
dc.date.available2018-05-07T07:05:11Z-
dc.date.issued2018-03-28-
dc.identifier.citationPLOS ONEen
dc.identifier.urihttp://hdl.handle.net/20.500.12323/3775-
dc.description.abstractMyeloperoxidase (MPO)-derived oxidants have emerged as a key contributor to tissue damage in inflammatory conditions such as cardiovascular disease. Pro-myeloperoxidase (pro-MPO), an enzymatically active precursor of myeloperoxidase (MPO), is known to be secreted from cultured bone marrow and promyelocytic leukemia cells, but evidence for the presence of pro-MPO in circulation is lacking. In the present study, we used a LC-MS/MS in addition to immunoblot analyses to show that pro-MPO is present in human blood plasma. Furthermore, we found that pro-MPO was more frequently detected in plasma from patients with myocardial infarction compared to plasma from control donors. Our study suggests that in addition to mature MPO, circulating pro-MPO may cause oxidative modifications of proteins thereby contributing to cardiovascular disease.en
dc.language.isoenen
dc.titleA myeloperoxidase precursor, promyeloperoxidase, is present in human plasma and elevated in cardiovascular disease patientsen
dc.typeArticleen
Appears in Collections:Publications



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.